13F Holdings
中文EN

SCYX SCYNEXIS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1178253 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY544.0%
TTM net income YoY60.1%
TTM EPS YoY127.8%
Revenue 3-yr CAGR-48.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-126.9%
Net margin-53.5%
FCF margin—
EBITDA margin—

Returns

ROE-21.2%
ROA-17.0%
ROIC (approx.)-52.4%
Asset turnover0.32x

Leverage & solvency

Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.19x
Accruals ratio3.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$20.60M$3.75M$140.14M$5.09M$13.16M
R&D expense$22.28M$26.41M$30.93M$27.26M$23.77M
SG&A expense$14.39M$14.46M$20.92M$62.96M$49.92M
Operating income-$16.07M-$37.12M$72.67M-$85.76M-$60.84M
Interest expense$173,000$828,000$3.13M$5.20M$2.66M
Pretax income-$8.61M-$21.14M$67.18M-$67.51M-$35.95M
Income tax$0$151,000$138,000-$4.70M-$3.09M
Net income-$8.61M-$21.29M$67.04M-$62.81M-$32.87M
EBITDA—-$37.12M$73.25M-$85.15M-$60.46M
EPS (basic)-0.17-0.441.40-1.47-1.25
EPS (diluted)-0.17-0.441.39-1.47-1.25
Weighted avg. shares (diluted)49.93M48.51M48.39M42.61M26.38M
Balance sheet
Cash & equivalents$21.26M$16.59M$34.59M$46.03M$104.70M
Short-term investments$18.77M$43.25M$40.31M$27.69M$0
Receivables——$0$2.10M$861,000
Inventory——$0$899,000$463,000
Current assets$40.37M$72.18M$102.12M$79.06M$109.38M
PP&E, net————$113,000
Intangibles——$0$408,000$1.06M
Total assets$59.03M$90.64M$128.41M$87.81M$119.84M
Current liabilities$5.73M$24.10M$16.30M$17.62M$13.62M
Short-term debt————$0
Long-term debt————$34.39M
Total debt————$34.39M
Total liabilities$9.65M$35.57M$55.45M$84.58M$78.58M
Shareholders' equity$49.38M$55.08M$72.96M$3.23M$41.26M
Net debt————-$70.31M
Shares outstanding5.44M37.97M37.21M32.68M28.71M
Cash flow statement
Operating cash flow-$5.28M-$24.01M$60.16M-$79.88M-$54.56M
Capital expenditure————$0
Free cash flow————-$54.56M
Investing cash flow$24.31M$6.15M-$34.88M-$27.39M-$1.17M
Financing cash flow-$14.17M-$139,000-$36.72M$48.60M$67.12M
Depreciation & amortization—$0$580,000$606,000$379,000
Stock-based compensation$2.85M$3.35M$2.62M$3.69M$2.09M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.